Medipharm Labs Corp T.LABS

Germany Booming

[QContinuum1]

https://www.n-tv.de/politik/Fragwuerdiges-Geschaeft-mit-Cannabis-auf-Rezept-boomt-article25056962.html

"Since the legalization of cannabis, the business with medical cannabis is booming. The behavior of some providers raises doubts about whether only patients are being targeted—or if the high demand is also coming from recreational users. The CDU (Christian Democratic Union, a major conservative political party in Germany) is alarmed, while the SPD (Social Democratic Party of Germany, another major political party) is undecided.

Cannabis arrives at the house via DHL (a major international courier service). As if it were a sweater or a new coffee machine. The only difference: a signature from the recipient is not enough; the delivery person also wants to see an ID card. Then the treatment can begin. The 20 grams, packaged in a vacuum-sealed bottle, is medical cannabis grown in Canada. Beforehand, the patient had to fill out an online questionnaire on one of the numerous platforms that, for fees ranging from 15 to 50 euros, offer a video consultation with specialized general practitioners. The conversation with the doctor, who also wants to see an ID card, lasts about five minutes. Medical condition? Previous experience with cannabis? This is followed by a recommendation for the type and dosage of cannabis. Then comes the prescription, which can be immediately submitted digitally to a mail-order pharmacy or taken in person to a specialized pharmacy.

So quick, so easy. The medical cannabis business in Germany is booming. This aspect of cannabis legalization receives little public attention. "Since April 1, the medical cannabis market has nearly doubled in Germany," says David Henn, CEO of the medical cannabis wholesaler Cannamedical, in an interview with ntv.de. The Bloomwell Group, which provides a digital platform for medical cannabis to both doctors and pharmacies, reports massive growth: The number of patients using the group's referral service increased by 1000 percent in April alone compared to the average of the previous twelve months."

[Starkicker]

The German market is nice but it's a false hope on moving the SP up. LABS sold $1.4M in Germany in Q1. Even if that doubles, which it won't in Q2, we're still talking miniscule sales. Australia is about the same.  The company’s sales of medical cannabis into the German market were $1.4 million, a 36% increase from the previous quarter. The majority of these sales (70%) were non

[QContinuum1]

Agreed 100%.  Which is something I have a hard time reconciling.  If the market is booming and we have a Stada in our corner, how is it that sales don't materially increase? The post was less a point about how much (or little really) that LABS sells in Germany, and more about the fact that the market is growing by leaps and bounds and LABS should be taking part.  If not, why

[Starkicker]

Yeah, good question.  There never seems to be a revenue bump with any of these partnerships and new market entries.  Back around 2018 LABS sent out all kinds of press releases about entering this market and that market, and nothing ever came of it revenue-wise. It all got old a long time ago. As piduck said, mid August will likely just be yet another letdown for shareholders. If it is

[QContinuum1]

I understand that they entered the markets perhaps prematurely and signed those partnerships in advance of real policies needed to engage in those markets.  That is not the case any longer (certainly not in Germany).  Germany needs to be much higher and now 2 years from now, but next Q and the Qs thereafter.